An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
This study is testing two different medication combinations to see which works better for advanced breast cancer that has specific genetic changes. Researchers want to find a more effective way to treat patients whose cancer has stopped responding to standard hormone therapies.
Adult men and women of any menopausal stage with advanced ER+/HER2- breast cancer and an ESR1 gene mutation can join. Participants must have previously tried certain hormone treatments without their cancer progressing for at least six months.
Participants are randomly assigned to receive one of two treatment combinations: either the drug lasofoxifene combined with abemaciclib, or fulvestrant combined with abemaciclib. Both options involve taking daily pills, and one option also includes monthly injections.
The study is currently open and actively recruiting patients at multiple medical centers, including locations in Arizona and California. Your study doctor can provide the exact clinic details closest to you.
- 1Comparing two different hormone-blocking drug combinations with a targeted cancer therapy
- 2Open to men and women with advanced ER+/HER2- breast cancer and a specific gene mutation
- 3Currently recruiting participants at select locations in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.